IGC Pharma Business Summary

IGC Pharma, Inc. (IGC) is a clinical-stage biotechnology company that generates revenue through a dual-track model comprising the sale of white-label over-the-counter (OTC) cannabinoid formulations and the development of proprietary biopharmaceutical assets. The company operates through two primary business segments: Life Sciences, which focuses on AI-driven drug discovery and clinical trials for Alzheimer’s disease and metabolic disorders, and Infrastructure, a legacy segment that has been strategically minimized to prioritize biotech operations. IGC’s flagship asset, IGC-AD1, is currently in a Phase 2 clinical trial (CALMA) targeting agitation in Alzheimer’s dementia, supported by its proprietary MINT-AD artificial intelligence platform for early detection and trial optimization. Within the competitive landscape, IGC contends with players such as Jazz Pharmaceuticals (GW Pharma), MIRA Pharmaceuticals, Hyasynth Bio, and MariMed, positioning itself as a niche specialist leveraging AI and cannabinoid science to address high-unmet-need neurodegenerative symptoms. The company is led by founder Ram Mukunda, a biomedical engineer and veteran executive who previously took Startec Global Communications public. The leadership team includes Claudia Grimaldi, who serves as Vice President, Principal Financial Officer (PFO), and Chief Compliance Officer, bringing a background in psychology and healthcare management to oversee international clinical operations. Other key executives include CFO John Selvaraj and Principal Accounting Officer Rohit Goel. IGC’s Board of Directors features high-profile political and industry figures, including Chairman Richard Prins, former U.S. Congressman Jim Moran, and health policy expert Terry Lierman, with former Virginia Governor Terry McAuliffe serving as a board advisor. Notable institutional backing includes positions from the Vanguard Group, BlackRock, and the Bradbury Strategic Investment Fund, reflecting a sophisticated investor base aligned with the company’s pivot toward AI-integrated pharmaceutical development.